Humans ; Aluminum/adverse effects* ; Pruritus/etiology* ; Skin Neoplasms ; Vaccination ; Hypersensitivity

We are presenting a rare case of a 71-year-old Filipino female with the presence of two skin cancers occurring simultaneously in two different regions of the body.

Patient noted symmetrical, erythematous, pruritic, eczematous patches and plaques on her inguinal areas five years prior to consultation. The patient also had a 2-year history of multiple pigmented papules and plaques on the forehead, left jaw, right cheek, lateral canthus of the left eye, and sternal area associated with occasional bleeding.

Skin examination showed symmetrical, irregularly shaped bright red moist plaques with finger-like projections measuring 26 cm x 9 cm on the vulva, inguinal areas, and intergluteal areas. The patient also had multiple pigmented papules and plaques with rolled borders located on the right forehead, lateral canthus of the left eye, right cheek, left jaw, and sternal area with measurements ranging from 0.3 x 0.4 cm to 1.5 x 2.0 cm in size.

Histological examination of the vulvar skin biopsy is signed out as extramammary Paget’s disease with positive immunohistochemical stain for Cytokeratin 7. A skin punch biopsy on the pigmented plaque on the right forehead is signed out as basal cell carcinoma.

This is the first known case of the simultaneous occurrence of extramammary Paget’s disease and basal cell carcinoma on different regions of the body. We speculate that the two tumors in our patient may have developed independently with no causal relationship, but we are attributing the occurrence of the patient’s carcinomas to her old age, prolonged sun exposure, and immunosuppression.

In recent years, there has been a significant global increase in skin cancer incidence, which continues to pose a significant challenge to public health. This retrospective study aimed to comprehensively characterize the epidemiology of histopathologically diagnosed skin cancers at the Department of Dermatology, Jose R. Reyes Memorial Medical Center from January 2013 to December 2022. The research encompassed an analysis of demographic and clinical profiles in 352 cases. The cases consisted of basal cell carcinoma (BCC) (161, 46%), squamous cell carcinoma (SCC) (62, 18%), melanoma (21, 6%), mycosis fungoides (MF) (37, 11%), other cutaneous T-Cell lymphomas (11, 3%), mammary Paget’s disease (7, 2%), extramammary Paget’s disease (6, 1.7%), Langerhans cell histiocytosis (LCH) (8, 2%), sebaceous carcinoma (3, 1%), Merkel cell carcinoma (MCC) (1, 0.3%), dermatofibrosarcoma protuberans (1, 0.3%), angiosarcoma (2, 0.6%), Kaposi sarcoma (3, 0.9%), and cutaneous metastasis (29, 8%). Among the primary cutaneous malignancies, BCC, SCC, MF, and melanoma were the most frequently encountered types. The findings reveal a notable upward trend in all skin cancer incidence, and projections suggest a continued increase in the next five years. BCC and SCC were more common in males and affected predominantly sun-exposed areas, while melanoma exhibited a slight female preponderance and primarily affected the lower extremities (acral melanoma). These skin cancers were more common among elderly individuals. The study highlights the need for standardized documentation to improve data quality on epidemiology. This, in turn, can lead to improved early detection, prevention, and better management of this escalating global public health issue.

BACKGROUND

Mohs micrographic surgery (MMS) is the preferred surgical procedure for non melanoma skin cancers (NMSCs), especially in areas where function and cosmesis are critical. It allows precise removal of the tumor while preserving normal skin tissue.

This study aimed to describe the clinicohistopathologic profile of patients who underwent MMS at the Dermatology Center of the St. Luke’s Medical Center, Quezon City, Philippines (SLMC-QC) from March 2003 to March 2023.

This was a descriptive cross-sectional study utilizing a 20-year chart review on all patients who underwent MMS at SLMC-QC from March 2003 to March 2023. Data collected were the following: age, sex, race, clinicopathologic diagnosis, tumor site, pre-operative and post-operative area size, number of MMS stages, type of repair performed, and recurrence, if any.

In 20 years, there were a total of 684 cases done in the Dermatology Center SLMC-QC, and 573 cases with complete data were included. Eighty six percent of patients were over 50 years old. There was a slight male predominance, and most patients were Asians, followed by Caucasians. Basal cell carcinoma was the most common diagnosis followed by squamous cell carcinoma and Bowen’s disease. Majority of the tumors were located on the head and neck. The postoperative defect increased by 2-to-3-fold from the preoperative tumor size in most cases. Most tumors were cleared in 2 stages. The most common type of repair done was flaps, followed by full-thickness skin grafts and primary closures. All primary tumors treated in the center have not recurred within 5 years, bringing the cure rate to 100%.

The clinicohistopathologic profiles of patients in this study are similar to those reported in the literature. No recurrence has been reported in the center and this reflects the effectivity of MMS.

Humans ; Melanoma/therapy* ; Immunotherapy ; Syndrome ; Skin Neoplasms

A 3-year-old boy presented with bluish patch and scattered blue spots on the left side of his face. After several sessions of laser treatment, the azury patch in the periorbital area became even darker. Histopathology showed many bipolar, pigment-laden dendritic cells scattered in the papillary and upper reticular dermis. Immunohistochemically, these cells were positive for S100, SOX-10, melan-A, P16, and HMB-45. The positive rate of Ki-67 was less than 5%. Finally, the lesion was diagnosed with nevus of Ota concurrent with common blue nevus. Therefore, for cases of the nevus of Ota with poor response to laser treatment, the possible coexisting diseases should be suspected.
Male ; Humans ; Child, Preschool ; Nevus, Blue/pathology* ; Nevus of Ota/therapy* ; Skin/pathology* ; Face ; Skin Neoplasms/pathology*

OBJECTIVE: To summarize the effectiveness of the temporal island flap pedicled with the perforating branch of zygomatic orbital artery for repairing defects after periocular malignant tumor resection. METHODS: Between January 2015 and December 2020, 15 patients with periocular malignant tumors were treated. There were 5 males and 10 females with an average age of 62 years (range, 40-75 years). There were 12 cases of basal cell carcinoma and 3 cases of squamous carcinoma. The disease duration ranged from 5 months to 10 years (median, 2 years). The size of tumors ranged from 1.0 cm×0.8 cm to 2.5 cm×1.5 cm, without tarsal plate invasion. After extensive resection of the tumors, the left defects in size of 2.0 cm×1.5 cm to 3.5 cm×2.0 cm were repaired with the temporal island flap pedicled with the perforating branch of zygomatic orbital artery via subcutaneous tunnel. The size of the flaps ranged from 3.0 cm×1.5 cm to 5.0 cm×2.0 cm. The donor sites were separated subcutaneously and sutured directly. RESULTS: All flaps survived after operation and the wounds healed by first intention. The incisions at donor sites healed by first intention. All patients were followed up 6-24 months (median, 11 months). The flaps were not obviously bloated, the texture and color were basically the same as the surrounding normal skin, and the scars at recipient sites were not obviously. There was no complication such as ptosis, ectropion, or incomplete closure of the eyelids and recurrence of tumor during follow-up. CONCLUSION The temporal island flap pedicled with the perforating branch of zygomatic orbital artery can repair the defects after periorbital malignant tumors resection and has the advantages of reliable blood supply, flexible design, and good morphology and function.
Male ; Female ; Humans ; Middle Aged ; Plastic Surgery Procedures ; Skin Transplantation ; Soft Tissue Injuries/surgery* ; Treatment Outcome ; Surgical Flaps ; Arteries/surgery* ; Carcinoma, Squamous Cell/surgery* ; Skin Neoplasms/surgery* ; Perforator Flap/blood supply*

OBJECTIVE: To explore the effectiveness of lobulated pedicled rectus abdominis myocutaneous flap to repair huge chest wall defect. METHODS: Between June 2021 and June 2022, 14 patients with huge chest wall defects were treated with radical resection of the lesion and lobulated pedicled rectus abdominis myocutaneous flap transplantation for reconstruction of chest wall defects. The patients included 5 males and 9 females with an average age of 44.2 years (range, 32-57 years). The size of skin and soft tissue defect ranged from 20 cm×16 cm to 22 cm×22 cm. The bilateral pedicled rectus abdominis myocutaneous flaps in size of 26 cm×8 cm to 35 cm×14 cm were prepaired and cut into two skin paddles with basically equal area according to the actual defect size of the chest wall. After the lobulated pedicled rectus abdominis myocutaneous flap was transferred to the defect, there were two reshaping methods. The first method was that the skin paddle at the lower position and opposite side was unchanged, and the skin paddle at the effected side was rotated by 90° (7 cases). The second method was that the two skin paddles were rotated 90° respectively (7 cases). The donor site was sutured directly. RESULTS: All 14 flaps survived successfully and the wound healed by first intention. The incisions at donor site healed by first intention. All patients were followed up 6-12 months (mean, 8.7 months). The appearance and texture of the flaps were satisfactory. Only linear scar was left at the donor site, and the appearance and activity of the abdominal wall were not affected. No local recurrence was found in all tumor patients, and distant metastasis occurred in 2 breast cancer patients (1 liver metastasis and 1 lung metastasis). CONCLUSION The lobulated pedicled rectus abdominis myocutaneous flap in repair of huge chest wall defect can ensure the safety of blood supply of the flap to the greatest extent, ensure the effective and full use of the flap tissue, and reduce postoperative complications.
Male ; Female ; Humans ; Adult ; Myocutaneous Flap/surgery* ; Plastic Surgery Procedures ; Thoracic Wall/surgery* ; Rectus Abdominis/transplantation* ; Skin Transplantation ; Breast Neoplasms/surgery* ; Soft Tissue Injuries/surgery* ; Treatment Outcome

OBJECTIVE: To explore the clinical characteristics, treatment, and prognosis of patients with blastic plasmacytoid dendritic cell neoplasm(BPDCN). METHODS: Clinical data of 5 patients diagnosed with BPDCN in Wuhan First Hospital and Wuhan Tongji Hospital from June 2016 to November 2021 were retrospectively analyzed. RESULTS: Among the 5 patients, 3 were male and 2 were female, with a median age of 28(10-52) years old. Four patients showed obvious skin damage at the initial diagnosis; the other one showed clinical manifestations of acute leukemia rather than obvious skin damage at the initial diagnosis, but infiltrated skin when the disease relapsed after treatment. Other infiltration sites of lesions included bone marrow (2/5), peripheral blood (2/5), lymph nodes (3/5), liver and spleen (2/5). All patients had no clinical manifestation of central nervous system infiltration. Tumor cell specific immune markers CD4, CD56, CD123 were all positive, and the median Ki-67 index was 70%. TET2, ASXL1 and NRAS gene mutations were found respectively in 3 patients by next-generation sequencing technique (NGS). ALL-like, AML-like and invasive NK/T cell lymphoma-like first-line induction chemotherapy regimens were used for the patients. One patient died of severe complications during the early stage of chemotherapy, 3 patients were evaluated as CR, and 1 patient was evaluated as PR. 2 patients were recurred and progressed after induction of chemotherapy, and one of them was evaluated as CR after re-treatment. One patient received autologous hematopoietic stem cell transplantation (auto-HSCT) and got long-term survival (OS 87 months). 3 patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT), of which one died of transplantation related complications, and 2 cases survived. The median follow-up time of 4 patients with evaluable efficacy was 28.5(9-84) months, the median OS time was 31.5(10-87) months. CONCLUSION BPDCN is a highly heterogeneous malignant tumor with a poor prognosis. HSCT, especially allo-HSCT can significantly improve the prognosis of BPDCN patients.
Humans ; Male ; Female ; Adult ; Middle Aged ; Retrospective Studies ; Leukemia/pathology* ; Hematopoietic Stem Cell Transplantation ; Prognosis ; Myeloproliferative Disorders ; Skin Neoplasms/pathology* ; Acute Disease ; Dendritic Cells

OBJECTIVES: Malignant melanoma is a highly malignant and heterogeneous skin cancer. Although immunotherapy has improved survival rates, the inhibitory effect of tumor microenvironment has weakened its efficacy. To improve survival and treatment strategies, we need to develop immune-related prognostic models. Based on the analysis of the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Sequence Read Archive (SRA) database, this study aims to establish an immune-related prognosis prediction model, and to evaluate the tumor immune microenvironment by risk score to guide immunotherapy. METHODS: Skin cutaneous melanoma (SKCM) transcriptome sequencing data and corresponding clinical information were obtained from the TCGA database, differentially expressed genes were analyzed, and prognostic models were developed using univariate Cox regression, the LASSO method, and stepwise regression. Differentially expressed genes in prognostic models confirmed by real-time reverse transcription PCR (real-time RT-PCR) and Western blotting. Survival analysis was performed by using the Kaplan-Meier method, and the effect of the model was evaluated by time-dependent receiver operating characteristic curve as well as multivariate Cox regression, and the prognostic model was validated by 2 GEO melanoma datasets. Furthermore, correlations between risk score and immune cell infiltration, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) score, immune checkpoint mRNA expression levels, tumor immune cycle, or tumor immune micro-environmental pathways were analyzed. Finally, we performed association analysis for risk score and the efficacy of immunotherapy. RESULTS: We identified 4 genes that were differentially expressed in TCGA-SKCM datasets, which were mainly associated with the tumor immune microenvironment. A prognostic model was also established based on 4 genes. Among 4 genes, the mRNA and protein levels of killer cell lectin like receptor D1 (KLRD1), leukemia inhibitory factor (LIF), and cellular retinoic acid binding protein 2 (CRABP2) genes in melanoma tissues differed significantly from those in normal skin (all P<0.01). The prognostic model was a good predictor of prognosis for patients with SKCM. The patients with high-risk scores had significantly shorter overall survival than those with low-risk scores, and consistent results were achieved in the training cohort and multiple validation cohorts (P<0.001). The risk score was strongly associated with immune cell infiltration, ESTIMATE score, immune checkpoint mRNA expression levels, tumor immune cycle, and tumor immune microenvironmental pathways (P<0.001). The correlation analysis showed that patients with the high-risk scores were in an inhibitory immune microenvironment based on the prognostic model (P<0.01). CONCLUSIONS The immune-related SKCM prognostic model constructed in this study can effectively predict the prognosis of SKCM patients. Considering its close correlation to the tumor immune microenvironment, the model has some reference value for clinical immunotherapy of SKCM.
Humans ; Melanoma/genetics* ; Skin Neoplasms/genetics* ; Tumor Microenvironment ; Prognosis